Skip to main content
Caplight Logo









Signadori Bio

Signadori Bio

Private
ParisHealthcare & Life Scienceshttps://www.signadoribio.com/

Last Round

Seed

May 6, 2026

Total Funding Raised

$13M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Signadori Bio is a biopharmaceutical company developing a next-generation, off-the-shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

monocyte immunotherapyin vivo immunotherapysolid tumor therapycell engineeringp21 proteinoff-the-shelf therapycancer immunotherapymyeloid cell reprogrammingtumor microenvironmentpreclinical biotechdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Signadori Bio Comparables

Compare Signadori Bio with similar companies based on industry and business-model similarity.

Signadori Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbbVie
80%
Liberate Bio
76%
CREATE Medicines
74%

Signadori Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 6, 2026

Key People

Founding team and executive leadership

Selwyn Ho

Chief Executive Officer

Executive Team

Signadori Bio Investors

Notable investors and investment history

Signadori Bio investors
InvestorRounds
Taiho VenturesSeed
Sofinnova PartnersSeed
Invivo PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 22, 2026

    Grew 75% QoQ from 4 to 7 employees.

  • May 6, 2026

    $13M round with Taiho Ventures and Invivo Partners.

Signadori Bio Filings

Explore SEC and related filing metadata, where available.

Signadori Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Signadori Bio's valuation, stock price, and market status.

Is Signadori Bio a public or private company?

Signadori Bio is a private company.

What is the current stock price of Signadori Bio?

Signadori Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Signadori Bio worth (valuation)?

Valuation information for Signadori Bio is not publicly available.

Can I buy Signadori Bio stock?

Signadori Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Signadori Bio's last funding round?

Signadori Bio's most recent funding round was Seed on May 6, 2026.

Who are the main investors in Signadori Bio?

Key investors in Signadori Bio include Taiho Ventures, Sofinnova Partners, Invivo Partners.

Will Signadori Bio IPO soon?

No public IPO plans have been announced for Signadori Bio.

How can I track Signadori Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Signadori Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range8
Year Founded2025
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?